Today’s guest post is from Reinhard von Roemeling, board certified oncologist and former SVP of global oncology at EMD-Serono/Merck KGaA.
Can adaptive trials change the way we treat Alzheimer's disease?
How are the world’s largest pharmaceutical companies adapting their R&D strategies to incorporate new technology that is putting the emphasis back on the patient?
Neuroscience, meet Donkey Kong. Can microprocessors help us understand inner workings of the brain?